ANN ARBOR, Mich.–(BUSINESS WIRE)—- $NDRA #MASLD–ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update. Business Update During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At th